Eli Lilly (LLY): Incretin Growth Still Drives the Story

Thesis

Eli Lilly (LLY) remains one of the strongest growth franchises in large-cap pharma, powered by a rare mix of commercial scale, clinical momentum, and manufacturing execution. The core investment case is straightforward: Lilly grew 2025 revenue 45% to $65.2B, then followed with Q1 2026 revenue of $19.799B, up 56% YoY, while reported EPS rose 170% to $8.26. That is not a story built on hope. It is a story built on products already moving through the income statement.

The engine is cardiometabolic health, especially Mounjaro and Zepbound, but the business is no longer a one-act show. In Q1 2026, key product revenue reached $13.4B, or 68% of total revenue, up 110% YoY. Outside that core, Lilly is adding growth from Ebglyss, Jaypirca, Omvoh, Kisunla, and Inluriyo, while also pushing the next wave through Foundayo, the newly approved oral GLP-1 orforglipron, and retatrutide. Management raised 2026 guidance on April 30, 2026 to $82B-$85B in revenue and $35.50-$37.00 in non-GAAP EPS, up from the prior $80B-$83B and $33.50-$35.00. When a company raises guidance from an already elevated base, that matters.

The main pushback is valuation. LLY trades at 37.0x trailing earnings and 25.9x forward earnings, with EV/revenue at 12.5x. Those are premium multiples, and the market is not handing them out for free. Lilly has earned much of that premium through 42.6% revenue growth, 51.4% earnings growth, 83.0% gross margin, and a pipeline that management described as one of the largest clinical-stage portfolios in company history. For a balanced, moderate-risk investor, the stock still looks attractive, but only if the premium is treated with discipline. This is a high-quality compounder, not a bargain-bin trade.

Company Overview

Eli Lilly and Company (LLY) is a global pharmaceutical company headquartered in Indianapolis, founded in 1876, with about 50,000 employees. It develops and markets human pharmaceutical products across cardiometabolic health, oncology, immunology, and neuroscience. The company operates globally, including the U.S., Europe, China, Japan, and other international markets.

The portfolio spans diabetes and obesity medicines such as Mounjaro, Zepbound, Jardiance, and Trulicity; oncology drugs including Verzenio, Jaypirca, Retevmo, and Erbitux; immunology products such as Taltz, Omvoh, Ebglyss, and Olumiant; and neuroscience assets including Emgality and Kisunla. That breadth matters because it gives Lilly multiple shots on goal, even though current growth is clearly concentrated in incretins.

Financially, Lilly has moved into a different league. Market cap stands at about $760.4B. Revenue reached $65.18B in 2025, up from $45.04B in 2024 and $34.12B in 2023. Net income rose to $20.64B in 2025 from $10.59B in 2024. Operating margin expanded to 45.6% in 2025 from 38.9% in 2024 and 31.6% in 2023. This is what scale looks like when a blockbuster franchise hits full stride.

Leadership is headed by Chairman and CEO David A. Ricks, with Lucas Montarce as CFO and Daniel Skovronsky as Chief Scientific and Product Officer. The current management team is not just selling a growth narrative. It is funding it, building capacity for it, and increasingly proving it quarter by quarter.

Business Segment Deep Dive

Lilly reports revenue primarily as Product and Collaboration and Other Revenue. In 2025, Product revenue was $60.96B, or 93.5% of total revenue, while Collaboration and Other Revenue was $4.22B, or 6.5%. That mix has shifted sharply toward product sales from 84.4% in 2023 and 90.5% in 2024, which shows how much the commercial portfolio is now carrying the business.

Within the operating business, cardiometabolic health is the center of gravity. In Q1 2026, Zepbound alone generated $4.2B, up 80% YoY. Lilly also said incretin revenue grew 90% in the quarter, with Mounjaro holding 51% U.S. total prescription share of market. In Q4 2025, management said Zepbound and Mounjaro both delivered strong results, with Mounjaro exiting the quarter with over 55% of new prescriptions in the U.S. type 2 diabetes incretin market and Zepbound holding nearly 70% share of new branded obesity prescriptions.

Immunology is smaller but growing quickly. Ebglyss delivered Q1 2026 sales of $145M, up 141% YoY, while Omvoh global revenue increased 55% in Q4 2025 versus the prior year quarter. Oncology is more mature but still productive. Jaypirca posted Q1 2026 sales of $165M, up 79% YoY, and management highlighted a recently expanded U.S. indication that broadens the eligible patient population. Inluriyo contributed $35M in Q1 2026 sales.

Neuroscience is becoming more relevant. Kisunla generated $124M in Q1 2026 sales after $109M in Q4 2025, and management said it became the U.S. market leader in amyloid-targeting therapy with more than 50% share of total prescriptions. That is still early revenue in the context of Lilly’s size, but leadership in a new category can become strategically important fast.

The practical takeaway is that Lilly is no longer just a legacy pharma company with one hot product cycle. It is becoming a platform business inside branded pharma, where one therapeutic success feeds manufacturing scale, payer leverage, commercial reach, and pipeline funding for the next one.

Flagship Product Analysis

The flagship franchise is tirzepatide, sold as Mounjaro for type 2 diabetes and Zepbound for obesity. This is the commercial heart of LLY. In Q4 2025, management said key products contributed over $13B of revenue in the quarter and grew 91% YoY, with volume growth in Mounjaro and Zepbound driving a 43% increase in Q4 revenue. In Q1 2026, the momentum continued, with total company revenue up 56% YoY and key product revenue up 110% YoY.

Zepbound has become the branded obesity market leader. Management said it held nearly 70% share of new prescriptions in Q4 2025, and Q1 2026 sales reached $4.2B, up 80% YoY. The company also said Zepbound self-pay vials made up one-third of new patient starts on any brand of obesity medication in 2025, and in Q4 the vial format represented about one-third of total Zepbound prescriptions and nearly 50% of new Zepbound prescriptions. That is not just demand. That is distribution innovation doing real work.

Mounjaro remains dominant in diabetes. In Q4 2025, Lilly said it exited the quarter with over 55% of new prescriptions in the U.S. type 2 diabetes incretin market. In Q1 2026, the company reported Mounjaro U.S. total prescription share of market at 51%. Outside the U.S., management said Lilly had launched in all major markets and had become the incretin share leader outside the U.S. as well.

The next flagship candidate is Foundayo, the oral GLP-1 orforglipron. CEO David Ricks said the FDA approval of Foundayo made it the only approved GLP-1 pill that can be taken any time of day without food and water restrictions. The product became broadly available in retail on April 9, 2026, was offered on more than 12 major telehealth platforms representing about 35% of launch volume, and had commercial access confirmed at two-thirds of major PBMs by mid-May. Lilly also said more than 80% of Foundayo prescriptions were new incretin patients. That matters because it points to market expansion, not just share shuffling.

The product stack is getting deeper, not narrower. That is the key distinction. Tirzepatide built the castle. Orforglipron and retatrutide are being positioned to widen the moat.

Innovation & Competitive Advantage

Lilly’s competitive advantage starts with science, but it does not end there. Management said the company generated positive clinical data in more than 25 Phase III trials in 2025 and started 14 new Phase III programs over the past few months, including oloralintide and brenepatide. Daniel Skovronsky said Lilly now has one of the largest clinical-stage pipelines in company history. In pharma, pipeline depth is the closest thing to future inventory.

The incretin portfolio is the clearest example of Lilly’s edge. Tirzepatide already leads in obesity and diabetes. Orforglipron extends the franchise into oral delivery. Retatrutide adds a next-generation triple agonist candidate. In the TRIUMPH-4 Phase III trial, retatrutide 12 mg produced average weight loss of 29% at 68 weeks in adults with obesity and knee osteoarthritis, while reducing WOMAC pain scores by 4.5 points, a 76% reduction in pain. Lilly expects six additional Phase III retatrutide readouts in 2026.

The company is also building scientific optionality beyond obesity. In oncology, pirtobrutinib reduced the risk of progression or death by 80% versus bendamustine plus rituximab in the BRUIN CLL-313 study, and in an early analysis of treatment-naive patients in BRUIN CLL-314, it reduced the risk by 76% versus ibrutinib. In immunology, Lilly reported a 64% relative increase in the proportion of patients achieving a 50% reduction in psoriatic arthritis symptoms when tirzepatide was added to ixekizumab versus ixekizumab alone. These are not side projects. They are evidence that Lilly is trying to reuse biological insight across categories.

Lilly is also leaning into AI-enabled drug discovery. David Ricks said the company announced a collaboration with NVIDIA to open a co-innovation AI lab, combining Lilly’s scientific expertise with NVIDIA’s technology. AI in pharma is often marketed like a magic wand. Here it looks more like a power tool: useful because Lilly already has the lab, the pipeline, and the budget to use it.

Operations & Supply Chain

Operations are central to the Lilly story because demand for incretin medicines has been strong enough to make manufacturing capacity a competitive weapon. Management said Lilly exceeded its goal to produce 1.8x the number of incretin doses in 2025 compared with 2024. It also began making medicine at new sites in Wisconsin and North Carolina and announced plans to build multiple new manufacturing sites in the U.S. and Europe.

Since 2020, Lilly has committed more than $55B to manufacturing expansion, which management called the largest build-out in company history. That spending is large, but it is rational. In obesity and diabetes, the company that can supply wins more than the company that simply publishes the best slide deck.

The financial results show that the operating model is holding up under scale. Gross margin reached 83.8% in 2025, up from 81.3% in 2024 and 79.2% in 2023. In Q4 2025, non-GAAP gross margin was 83.2%, and in Q1 2026 it was 82.6% on a non-GAAP basis. Management said favorable product mix and improved production costs offset some of the drag from lower realized prices and new facilities coming online.

There is still friction. Lilly said price was a 13% drag on Q1 2026 revenue growth and a 7% drag in the U.S. in Q4 2025. Management also said 2026 price will be pressured by the government obesity access agreement, updated direct-to-patient Zepbound pricing, lower Medicaid prices for later-life-cycle medicines, and Mounjaro’s inclusion on China’s National Reimbursement Drug List. That means operations must keep productivity rising to protect margins. So far, they are doing that.

Market Analysis

Lilly operates in a pharmaceutical market growing at a modest pace overall, but its real opportunity sits in the much faster-growing obesity and cardiometabolic category. Lilly’s 2025 investor materials described an outside-U.S. addressable market of about 1 billion patients with obesity or overweight plus an obesity-related comorbidity. That is the sort of number that explains why investors are willing to pay premium multiples for category leaders.

The market is also expanding by format, not just by diagnosis. Management said obesity penetration remains only in the mid-single digits and that oral GLP-1s should expand the addressable market. Foundayo’s early launch data support that view, with more than 80% of prescriptions coming from new incretin patients. If injectables opened the category, oral therapy can widen the door.

Geographic expansion is another tailwind. In Q1 2026, Europe revenue was $3.646B, up 53% at constant exchange rates, China revenue was $693M, up 52% CER, Japan revenue was $571M, up 42% CER, and rest-of-world revenue was $2.771B, up 168% CER. That is broad-based demand, not a single-country spike.

The market backdrop is attractive, but it is not frictionless. Pricing pressure is intensifying, payer access remains selective, and obesity coverage still moves in uneven steps. Even so, Lilly’s current growth profile shows that volume is more than compensating for price pressure. In Q1 2026, total revenue growth was driven by volume up 65%, FX up 4%, and price down 13%.

Customer Profile

Lilly’s end customers are patients, physicians, hospitals, health systems, payers, and pharmacy benefit managers, but the practical commercial focus is clear: large chronic-disease populations where persistence, access, and convenience drive repeat demand. In obesity and diabetes, the company is targeting both traditional reimbursed channels and cash-pay or direct-to-patient pathways.

The direct-to-patient model is becoming a meaningful part of the commercial toolkit. Management said the number of people engaging with Lilly’s U.S. direct-to-patient platform reached 1 million in 2025. The company also said Zepbound self-pay vials became its most popular offering and accounted for one-third of new patient starts on any brand of obesity medication. That is a strong sign that Lilly is not waiting for every payer to cooperate before building demand.

Customer adoption patterns also show a split between mature and emerging products. Mounjaro and Zepbound are already category leaders with broad physician uptake. Kisunla’s growth has been tied to increased awareness, diagnosis, and prescriber adoption in Alzheimer’s disease. Foundayo’s early prescription mix, with more than 80% new incretin patients, points to a convenience-driven customer segment that may not have entered the injectable market.

Institutional ownership of 84.8% also says something about the shareholder customer base: this is a stock owned heavily by large, long-duration capital. Short interest is minimal at 1.02% of float, and the short ratio is 2.7. That does not guarantee stability, but it does suggest the shareholder base is not built around a crowded bearish trade.

Competitive Landscape

The main competitive battleground is obesity and diabetes, where Novo Nordisk is Lilly’s primary rival. Industry context notes that Lilly’s head-to-head SURMOUNT-5 data showed Zepbound outperformed Wegovy on weight loss, reinforcing Lilly’s efficacy edge. In the market, Lilly reported Zepbound held nearly 70% share of new branded obesity prescriptions in Q4 2025, while Mounjaro held 51% U.S. total prescription share of market in Q1 2026.

That does not mean the field is settled. Novo remains a formidable competitor with global scale, deep obesity focus, and established commercial infrastructure. Lilly also faces pressure from compounded and illegal copycat products, a risk the company explicitly flags in its disclosures. In obesity, convenience, supply, and access can matter almost as much as efficacy. The best molecule does not always win every prescription if the supply chain or reimbursement engine sputters.

Outside cardiometabolic health, Lilly competes with Pfizer, Amgen, AbbVie, Sanofi, Takeda, J&J, and others across oncology and immunology. In those categories, Lilly’s position is more mixed. Verzenio remains a market leader in early breast cancer, but management said U.S. market penetration has reached a plateau. Jaypirca, Ebglyss, Omvoh, and Kisunla are earlier in their growth curves and offer a path to broader diversification.

Lilly’s edge is not that it faces weak competition. It is that it currently has the better combination of commercial momentum, manufacturing expansion, and pipeline sequencing in the hottest therapeutic category in pharma.

Macro & Geopolitical Landscape

Lilly’s macro exposure is unusual for a pharma company because demand is global, but pricing and access are deeply political. In 2026, management said price will be pressured by the U.S. government access agreement for obesity medicines, updated direct-to-patient Zepbound pricing, lower Medicaid prices for later-life-cycle medicines, and Mounjaro’s inclusion on China’s National Reimbursement Drug List. That is a reminder that blockbuster demand does not exempt a company from policy gravity.

The policy picture cuts both ways. Lilly said new Medicare access to obesity medicines is expected to become effective no later than July 1, 2026, which expands access for a large patient base. At the same time, management said some Medicaid coverage will be reduced in 2026 because key states such as California are removing obesity coverage. In plain English, access is broadening in one lane while narrowing in another.

Geographically, Lilly is benefiting from strong international growth. Q1 2026 showed double-digit or better growth across Europe, Japan, China, and rest-of-world. China is especially notable because revenue rose 52% CER to $693M, driven by Mounjaro’s inclusion on the reimbursement list, though management also noted lower price in that market. Volume is doing the heavy lifting.

Macro volatility matters less to Lilly than to cyclical industries because medicine demand is relatively defensive. The bigger external risks are reimbursement pressure, regulatory timing, biosimilar and generic competition in older franchises, and geopolitical supply-chain complexity as the company expands manufacturing across regions.

Balance Sheet Health

Income Statement Strength

Estimates Outlook

Valuation Assessment

Target Prices & Recommendation

Closing

Eli Lilly (LLY) is doing what investors usually ask for and rarely get all at once: rapid growth, rising margins, raised guidance, manufacturing expansion, and credible pipeline depth. Revenue reached $65.2B in 2025, then accelerated again to $19.799B in Q1 2026. Reported EPS hit $8.26 in the quarter, and management lifted full-year guidance after just one quarter. Those facts put Lilly in a very short list of large-cap healthcare names with genuine operating momentum.

The caution is valuation, not business quality. Lilly is priced as a leader because it is one. For moderate-risk investors with a medium-term horizon, that still supports a Buy rating, especially below the fair value estimate of $1,150. The market has already recognized the story. The opportunity now is owning a premium franchise without paying a reckless price for it.